Conference Activities & Talks -

1. 児玉 祐一, 西 眞範, 佐藤 篤, 今村 知世, 出口 隆生, 平川 晃弘, 清河 信敬, 大木 健太郎, 嶋 晴子, 加藤 啓輔, 加藤 元博, 河崎 裕英, 坂口 大俊, 平松 英文, 後藤 裕明, 山本 将平, 伊藤 正樹, 谷澤 明彦, 湯坐 有希, 齋藤 明子, 小川 千登世, 多賀 崇, 足立 壯一, 嶋田 博之. 小児再発・難治フィラデルフィア染色体陽性白血病に対するポナチニブ安全性確認試験. 日本血液学会学術集会 2023.10.01

2. 大森 寛行, 川瀬 世史明, 水上 拓也, 谷垣 徹, 平田 哲夫, 大久保 宗則, 神谷 宏樹, 平川 晃弘, 川崎 雅規, 近藤 武, 鈴木 孝彦, 松尾 仁司. 心筋虚血とプラーク診断におけるAI画像診断　Virtual FFRとAI. 日本心血管インターベンション治療学会抄録集 2023.08.01

3. Arai H, Sugimoto T, Akatsu H, Doi T, Fujiwara Y, Hirakawa A, Kinoshita F, Kuzuya M, Lee S, Matsuo K, Michikawa M, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Suzuki H, Takechi H, Takeda S, Umegaki H, Wakayama S, Sakurai T, J-MINT study group. The Japan-multimodal intervention trial for prevention of dementia (J-MINT): a multi-center, randomized, 18-month controlled trial. AAIC 2023 2023.07.16

4. 田中 一, 布川 裕規, 山本 浩平, 谷本 幸介, 竹本 暁, 蓮見 壽史, 平川 晃弘, 石川 雄大, 福田 翔平, 早稲田 悠馬, 吉田 宗一郎, 横山 みなと, 藤井 靖久. 淡明細胞型腎細胞癌における腎実質浸潤/進展の意義　予後への影響と遺伝学的背景(Renal parenchymal infiltration or micronodular spread in clear cell renal cell carcinoma: prognostic impact and genomic backgrounds). 日本泌尿器科学会総会 2023.04.01

5. Tsuchiya K, Nagahori M, Hanazawa R, Sasaki S, Sato H, Hirakawa A, Anzai T, Takahashi K, Kobayashi Y, Hibiya S, Takenaka K, Watanabe M. Serial daily recording of patient-reported outcomes (PRO2) might predict treatment change in the patients with ulcerative colitis. ECCO 2023 2023.03.01

6. Uemura Y, Yamamoto M, Ishimura M, Kanegane H, Sawada A, Hirakawa A, Imadome K, Yoshimori M, Nagata M, Shimizu N, Koike R, Arai A.. Phase II Study of a JAK1/2 Inhibitor Ruxolitinib for Systemic Chronic Active Epstein-Barr Virus Disease: An Investigator-Initiated Trial. . ASH 2022 2022.12.10

7. Sato H, Sasaki M, Hirakawa A. Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents.. 2022 WNAR Annual Meeting 2022.06.13

8. Sato H, Sasaki M, Hirakawa A.. Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents.. 2022 WNAR Annual Meeting 2022.06.13

9. Ikeda S, Kudo R, Yamashita, Y, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Tateishi U, Hirakawa A, Akita H, Matsubara H, Nishihara H, Ishioka C, Sueoka-Aragane N, Muto M, Toyooka S. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. . Annual Meeting, American Society of Clinical Oncology 2022.06.05

10. Arakawa A, Ozawa H, Hirakawa A, Sadachi R, Hoshina Y, Tomatsuri S, Saito Y, Ando R, Terashima K, Nakamura K, Ogawa C. A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.. Annual Meeting, American Society of Clinical Oncology 2022.06.03

11. Kojima Y, Shimizu T, Yonemori K, Koyama T, Matsui N, Kamikura M, Tomatsuri S, Sumiyoshi Okuma H, Shimoi T, Noguchi E, Sudo K, Hirakawa A, Sadachi S, Okita N, Nakamura K, Yamamoto N, Fujiwara Y.. A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra- rare cancer with a highly life-threatening unmet needs（NCCH1806/MK004）. ESMO Congress 2021 2021.09.16

12. Hasegawa K, Nishikawa T, Hirakawa A, Kawasaki M, Tomatsuri S, Nagasaka Y, Nakamura K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Yoshida H, Yonemori K. . Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE TRIAL, NCCH1615): A MULTICENTER, PHASE 2 CLINICAL TRIAL. . ESMO Congress 2021 2021.09.16

13. Kudo R, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Akita H, Matsubara H, Nishihara H, Ishioka C, Aragane N, Muto M, Toyooka S,1 Tateishi U, Hirakawa A, Miyake S, Ikeda S.. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial). ASCO 2021.06.04

14. Kawai A, Nishikawa T, Kawasaki M, Tomatsuri S, Okamura N, Ogawa G, Hirakawa A, Shibata T, Nakamura K, Kakunaga S, Tamura K, Ando M, Ozaki T, Ueda T, Yonemori K. . Efficacy and Safety of Nivolumab Monotherapy in Patients with Unresectable Clear Cell Sarcoma and Alveolar Soft Part Sarcoma (OSCAR t rial, NCCH1510): A Multicenter, Phase 2 Clinical Trial OSCAR.. CTOS 2020 Annual Meeting 2020.11.18

15. Asano J, Hirakawa A.. An Empirical Bayesian Basket Trial Design Accounting for　Uncertainties of Homogeneity and Heterogeneity of Treatment Effect among Subpopulations. . ENAR 2020 Spring Meeting 2020.03.22

16. Hirakawa A. An experience of data sharing utilization. 第16回DIA日本年会 2019.11.11

17. Hirakawa A. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: application to basket trial data. 6th International Society of Biopharmaceutical Statistics 2019.08.26

18. Hirakawa A. Single-pivotal basket trials for rare cancer development in Japan.. 2019 the Japanese Society of Medical Oncology Annual Meeting, 2019.07.19

19. Hirakawa A. A clustering-based basket design. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

20. Hirakawa A. . A clustering-based basket design.. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

21. Hirakawa A, Sadachi R. A Basket Trial Design using Bayesian Model Averaging. ENAR 2019 Spring Meeting 2019.03.24

22. Tanaka Y, Sozu T, Hirakawa A.. Dose-Finding Method for Molecularly Targeted Agents Incorporating the Relative Dose Intensity in Phase I Oncology Clinical Trials.. ENAR 2019 Spring Meeting 2019.03.24

23. Sadachi R, Hirakawa A.. Heterogeneity Assessment of Treatment Effect among Subpopulations in Basket Trials. . ENAR 2019 Spring Meeting 2019.03.24

24. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, Hirakawa A, Sakai T, Shimizu K, Kobayashi E, Gokita T, Okamoto T, Matsunobu, T. . Significant risk factors of local recurrence after surgery in extra-peritoneal desmoid-type fibromatosis: a multicenter study in Japan.. The CTOS 2018 Annual Meeting 2018.11.14

25. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, Hirakawa A, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y. . MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. . ESMO 2018.10.19

26. Hirakawa A. Adaptive Designs in Clinical Trials. ICPM 2018: 20th International Conference on Psychosomatic Medicine 2018.09.27

27. Asano J, Hirakawa A.. An evaluation and modification of Simon's basket design in oncology. . International Society of Clinical Biostatistics 2018.08.26

28. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, Hirakawa A, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y.. MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. . ASCO 2018.06.01

29. Hirakawa A. Two-stage dose and zone finding method for two agent combination phase 1/2 trials. 2nd Pacific Rim Cancer Biostatistics Workshop 2017.10.12

30. Hirakawa A. . Two-stage dose and zone finding method for two agent combination phase 1/2 trials.. Pacific Rim Cancer Biostatistics Workshop 2017.10.12

31. Hirakawa A. Statistical Consideration for Novel Dose Escalation Methods in Phase 1 Oncology Trials. 2nd NCCH Workshop 2017.07.23

32. Kakurai Y, Hirakawa A, Hamada C. . Dose individualization based on multiple gene mutations for molecularly targeted agents.. 日本計量生物学会年会 2017.03.16

33. Hirakawa A, Kakurai Y, Kaneko S, Hamada C. Dose individualization based on multiple gene mutations for molecularly targeted agents. 37th International Society for Clinical Biostatistics 2016.08.21

34. Hirata T, Kawase Y, Kikuchi J, Hirakawa A, Okamoto S, Omori H, Nakatani Y, Ota H, Saigusa T, Miyake T, Kawamura I, Okubo M, Tsuchiya K, Matsuo H.. The validation of the ischemic cut off of IFR and IFRa (During Hyperemia), to predict the ischemic threshold of FFR.. 第80回日本循環器学会学術集会 2016.03.18

35. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Arioka Y, Oya-Ito T, Kushima I, Nakamura Y, Shiino T, Mori D, Maeda T, Tanaka S, Hamada S, Noma H, Yoshida M, Noda Y, Nagai T, Yamada K, Ozaki N.. The development of molecular diagnostic tool for schizophrenia using lymphoblastoid cell lines.. US HUPO 2016 Conference 2016.03.13

36. Hirakawa A. A Data-Driven Clustering Method Using a Mixture Approach of Nonlinear Mixed-Effects Model for Longitudinal Functional Rating Scale in Amyotrophic Lateral Sclerosis Patients. East Asia Regional Biometric Conference 2015 2015.12.20

37. Shimamura F, Hirakawa A, Hamada C.. Dose Finding Design for Two-Agent Combination Trials. . East Asia Regional Biometric Conference 2015 2015.12.20

38. Kaneko S, Hirakawa A, Hamada C.. Establishing Individualized Treatment Rules Based on Bayesian Model Averaging Approach.. East Asia Regional Biometric Conference 2015 2015.12.20

39. Sato H, Hirakawa A, Hamada C.. An Adaptive Dose-Finding Method Using a Change-Point Model for Molecularly Targeted Agents in Phase I Trials.. East Asia Regional Biometric Conference 2015 2015.12.20

40. Shimoi T, Yonemori K, Hirakawa A, Kinoshita F, Bun S, Shimomura S, Kodaira M, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. . Is there a relationship between oncology drugs’ costs and efficacy? . European Society for Medical Oncology 2015.09.25

41. Kawachi A, Yonemori K, Hirakawa A, Kinoshita F, Tamura K, Fujiwara Y, Takebe N. . Incidence and risk factors in interstitial lung disease in Cancer Therapy Evaluation Program phase I trials. . European Society for Medical Oncology 2015.09.25

42. Shimura M, Gosho M, Hirakawa A.. A comparison of conditional bias-adjusted estimators of a treatment difference for continuous data in group sequential designs.. Royal Statistical Society 2015.09.07

43. Asano J, Hirakawa A.. A novel C-statistic for evaluating prediction accuracy in a cure model for censored survival data with long-term survivors. . 36th Annual Conference of the International for Clinical Biostatistics 2015.08.23

44. Hirakawa A. Dose-finding designs for combination therapies in oncology. 1st Pacific Rim Cancer Biostatistics Workshop 2015.08.14

45. Hashimoto J, Koizumi F, Okuma H, Hirakawa A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.. Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis. 第13回日本臨床腫瘍学会学術集会 2015.07.16

46. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saiot T. . Optimal debulking surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.. 2015 Annual Meeting of the American Society of Clinical Oncology 2015.05.29

47. Sato H, Hirakawa A, Hamada C.. Dose-finding approach based on efficacy and toxicity outcomes in phase I oncology trials for molecularly targeted agents.. The 2015 ENAR Spring Meet 2015.03.11

48. Shimada K, Shimada S, Sugimoto K, Hayakawa F, Katayama M, Hirakawa A, Takagi Y, Nakamura S, Seto M, Naoe T, Tomita A, Kiyoi H.. Development and analysis of novel intravascular large B-cell lymphoma NOD/Shi-scid IL2Rγnull mouse xenograft model.. The 56th Annual Meeting of the American Society of Hematology 2014.12.06

49. Yoshimi A, Aleksic B, Kunimoto S, Kushima I, Nakamura Y, Kimura H, Takasaki Y, Wang C, Xing J, Hirakawa A, Ikeda M, Iwata N, Ozaki N.. Transcriptome analysis of lymphoblastoid cell line from schizophrenia and bipolar disorder. . XXII World Congress of Psychiatric Genetics 2014.10.16

50. Kato T, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Hirakawa A, Iwano S, Yokoi K. . The contact length between the tumor contour and lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma. . 28th Annual Meeting of the European Association for Cardio-Thoracic Surgery 2014.10.11

51. Asano J, Hirakawa A, Hamada C.. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model. . 35th International Society for Clinical Biostatistics 2014.08.24

52. Nara E, Yunokawa M, Yonemori K, Doutani C, Shimizu K, Mimaki Y, Oomatsu N, Komatsu M, Hirakawa A, Shimizu C, Fujiwara Y, Tamura K.. Identifying the social support needs of young cancer patients in Japan. . European Society of Medical Oncology 2014.06.25

53. Tanaka R, Yonemori K, Hirakawa A, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. . Risk factors for developing skeletal-related events associated with metastatic breast cancer patients receiving bone-modifying agents.. European Society of Medical Oncology 2014.06.25

54. Okuma H, Koizumi F, Hirakawa A, Nakatochi M, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. . Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis.. European Society of Medical Oncology 2014.06.25

55. Yoshimi A, Kunimoto S, Yamada S, Aleksic B, Hirakawa A, Nagai T, Ozaki N. . Proteomic analysis of the lymphoblastoid cell line derived from Japanese schizophrenic patients. . 29th CINP World Congress of Neuropsychopharmacology 2014.06.22

56. Usami N, Yokoi K, Murotani K, Hirakawa A, Tabata C, Soejima T, Kamikonya N, Tanaka F, Yamanaka T, Okada M, Hasegawa S, Nakano T. . Assessment of postoperative complications after the first all Japan multi-institutional trial of induction chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.. 15th World Conference on Lung Cancer 2013.10.27

57. Nara E, Kodaira M, Hirakawa A, Noguchi E, Yamamoto H, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. . Risk factors of eribulin mesylate. 第11回日本臨床腫瘍学会学術集会 2013.08.29

58. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model. . 34th International Society for Clinical Biostatistics 2013.08.25

59. Kakurai Y, Sano M, Hirakawa A, Hamada C.. A dose-finding approach based on cohort partitioning for combination of two agents in Phase I trials in oncology.. 34th International Society for Clinical Biostatistics 2013.08.25

60. Nomura S, Hirakawa A, Hamada C.. Sample size calculation for confirming both PFS and OS simultaneously in cancer clinical trials.. 34th International Society for Clinical Biostatistics 2013.08.25

61. Hirakawa A, Hamada C. . A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. . XXVIth International Biometrics Conference 2012.08.26

62. Yamada K, Hirakawa A, Hamada C. . Operating characteristics of the penalized Cox regression analysis in high-dimensional microarray data.. XXVIth International Biometrics Conference 2012.08.26

63. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. . XXVIth International Biometrics Conference 2012.08.26

64. Mano H, Hirakawa A, Hamada C.. Improvement of Trim and Fill method to adjust publication bias in meta-analysis using the clinical trial registration system. . XXVIth International Biometrics Conference 2012.08.26

65. Atsumi J, Hirakawa A, Hamada C.. A new allocation method for balancing prognostic continuous and categorical variables in clinical trials.. XXVIth International Biometrics Conference 2012.08.26

66. Asakawa T, Hirakawa A, Hamada C.. A dose-finding method using bayesian model averaging for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.. XXVIth International Biometrics Conference 2012.08.26

67. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model. . XXVIth International Biometrics Conference 2012.08.26

68. Hirakawa A, Hamada C. . An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. . XXVIth International Biometrics Conference 2012.08.26

69. Hirakawa A, Hamada C.. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.. 3rd East Asia Regional Biometric Conference 2012.02.02

70. Asano J, Hirakawa A, Hamada C.. A stepwise variable selection for a cure model.. 3rd East Asia Regional Biometric Conference 2012.02.02

71. Kaneko S, Yamada K, Hirakawa A, Hamada C.. Estimating the false positive rate in a high-dimensional regression model in cancer prognostic studies with microarrays. . 3rd East Asia Regional Biometric Conference 2012.02.02

72. Hirakawa A, Kaneko S, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. . Pacific Symposium on Biocomputing 2012.01.03

73. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. 日本バイオインフォマティクス学会 2011.11.08

74. Hirakawa A, Hamada C.. Sample size calculation for a regularized t-statistic in microarray experiments. 日本バイオインフォマティクス学会 2011.11.08

75. Yonemori K, Hirakawa A, Ryushima Y, Saito M, Yamamoto H, Hirata T, Ando M, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yamamoto H, Fujiwara Y.. Content analysis of “the guidance for proper usage” that are distributed to medical oncologists for promoting oncology pharmaceutical safety. . European Multidisciplinary Cancer Congress 2011.09.23

76. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, Hirakawa A, Shimizu C, Kinoshita T, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y.. Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity.. 第9回 日本臨床腫瘍学会学術集会 2011.07.21

77. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Kodaira M, Tomomatsu J, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Tsuda H, Fujiwara Y. . Molecular profiling (MP) as a possible prognostic marker for patients with cancer of unknown primary (CUP) treated using platinum doublet (PD) chemotherapy.. 第9回 日本臨床腫瘍学会学術集会 2011.07.21

78. Harano K, Kojima Y, Hashimoto K, Ando M, Hirakawa A, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Makimoto A, Fujiwara.. Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, d-actinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy. . Annual Meeting, American Society of Clinical Oncology 2011.06.03

79. Hashimoto K, Sasajima M, Ando M, Yonemori K, Hirakawa A, Tsuda H, Fujiwara Y.. Molecular profiling as a possible prognostic marker for patients with cancer of unknown primary treated using platinum doublet chemotherapy. . Annual Meeting, American Society of Clinical Oncology 2011.06.03

80. Asano J, Hirakawa A.. Covariate selection method in mixture cure model for survival data. . Eastern North American Region/International Biometric Society 2011.03.20

81. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, Hirakawa A, Shimizu C, Kinoshita, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y. . Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity. . 22nd International Congress on Anti Cancer Treatment 2011.02.01

82. Yamamoto H, Yonemori K, Hirakawa A, Shimizu C, Ando M, Katsumata N, Tamura K, Kinoshita T, Tsuda H, Fujiwara Y.. Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy. . European Society for Medical Oncology Congress 2010.10.08

83. Hirakawa A, Hamada C, Yoshimura I.. A practical comparison of response-adaptive randomizations in clinical trials with binary responses.. 31th International Society of Clinical Biostatistics 2010.08.29

84. Hirakawa A, Hamada C, Yoshimura I. . Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. . 31th International Society of Clinical Biostatistics 2010.08.29

85. Hirata T, Yonemori K, Ando M, Hirakawa A, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. . Efficacy of taxane regimens in patients with metastatic angiosarcoma. . 21st International Congress on Anti-cancer Treatment 2010.02.01

86. Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S.. Participation of elderly patients in registered clinical trials for cancer drug applications in Japan. . The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

87. Kotani N, Katsumata N, Yonemori K, Hirakawa A, Yamamoto H, Ono M, Hirata T, Yunokawa M, Kouno T, Shimizu C, Tamura K, Fujiwara Y. . Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer. . The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

88. Hashimoto K, Yonemori K, Shimizu C, Hirakawa A, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Fujiwara Y. . Identification of clinical decision making factors in the treatment of geriatric patients with metastatic or recurrent breast cancer.. The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

89. Hashimoto K, Yonemori K, Katsumata N, Hirakawa A, Shimizu C, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y.. Prediction of progressive disease using tumor marker in breast cancer patients without target lesion in first-line chemotherapy.. ASCO Breast Cancer Symposium 2009.10.08

90. Hirata T, Yonemori K, Hirakawa A, Kouno T, Shimizu C, Tamura K, Ando M, Katsumata N, Fujiwara Y.. A retrospective comparison of pleural progression free survival between systemic therapy alone and pleurodesis followed by preceding systemic therapy in breast cancer patients with malignant pleural effusion. . ASCO Breast Cancer Symposium 2009.10.08

91. Hirakawa A, Hamada C, Yoshimura I. . Sample size calculation for a regularized t-statistic in microarray experiments.. 30th International Society of Clinical Biostatistics 2009.08.23

92. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. An adjusted test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray experiments. . XX IVth International Biometric Conference 2008.07.13

93. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. A test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray data analysis.. 1st East Asia Regional Biometrics Conference 2007.12.09

94. Hirakawa A, Sato Y, Hamada C, Yoshimura I. . A statistical method to estimate sensitivity and specificity for identifying marker genes with microarray data. . 28th International Society of Clinical Biostatistics 2007.07.29

95. Hirakawa A, Sato Y, Sozu T, Hamada C, Yoshimura I.. Estimating the false discovery rate using a normal mixture distribution with microarray data.. XX III International Biometric Conference 2006.06.16

96. Sato Y, Ando H, Hirakawa A, Suganami H, Hamada C, Yoshimura I, Yoshida T, Yoshimura K. . Multiple imputation method for SNP typing data in linkage disequilibrium mapping of polygenic traits. . Joint Statistical Meetings 2005.08.07